Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers
- 597 Downloads
Background and Objectives
Suboxone® is a sublingual tablet of buprenorphine/naloxone, approved for the treatment of opioid dependence. The objective of this study was to quantify the impact of hepatic impairment or hepatitis C virus infection on the pharmacokinetics of buprenorphine or naloxone and their major metabolites.
Forty-three subjects received a single dose of a Suboxone 2.0/0.5-mg tablet. Blood samples were collected up to 168 h and pharmacokinetic parameters were calculated using non-compartmental analysis. Statistical analysis was performed using analysis of covariance.
Pharmacokinetic parameters were derived from 33 subjects. Compared with healthy subjects, for patients with severe hepatic impairment, total and peak exposures increased to 281.4 % [90 % confidence interval 187.1–423.3] and 171.8 % [117.9–250.2] for buprenorphine, 1401.9 % [707.6–2777.5] and 1129.8 % [577.2–2211.4] for naloxone. For moderate hepatic impaired subjects, naloxone total and peak exposure increased to 317.6 % [164.9–611.5] and 270.0 % [141.9–513.9]. For buprenorphine, only total exposure increased to 163.9 % [110.8–242.3]. Changes in maximum observed plasma concentration, area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration, and area under the plasma concentration-time curve from time zero to infinity of buprenorphine or naloxone in subjects with mild hepatic impairment or with hepatitis C virus infection were within twofold of those of healthy subjects. Serious adverse events were not observed.
Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone [Registered at ClinicalTrials.gov as NCT01846455]
KeywordsNaloxone Buprenorphine Hepatic Impairment Plasma Protein Binding Opioid Dependence
This work was sponsored and supported by Reckitt Benckiser Pharmaceuticals Inc.
Declaration of conflict of interest
The authors all are full-time employees of Reckitt Benckiser Pharmaceuticals Inc.
- 1.Substance Abuse and Mental Health Services Administration. Results from the 2012 national survey on drug use and health: summary of national findings, NSDUH series H-46, HHS Publication No. (SMA) 13-4795. Rockville: Substance Abuse and Mental Health Services Administration; 2013.Google Scholar
- 2.CDC. Vital signs: prescription painkiller overdoses in the US. Morb Mort Weekly Rep. http://www.cdc.gov/vitalsigns/PainkillerOverdoses/index.html. Accessed 29 Sept 2014.
- 3.American Society of Addiction Medicine (ASAM). Advancing access to addiction medications: implications for opioid addiction treatment; 2013.Google Scholar
- 5.Reckitt Benckiser Pharmaceuticals Inc. Suboxone sublingual tablet product label; 2014.Google Scholar
- 12.Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Disp. 1998;26:818–21.Google Scholar
- 21.Netzer P, Sendensky A, Wissmeyer MP, et al. The effect of naloxone-3-glucuronide on colonic transit time in healthy men after acute morphine administration: a placebo-controlled double-blinded crossover preclinical volunteer study. Aliment Pharmacol Ther. 2008;28:1334–41.PubMedCrossRefGoogle Scholar
- 23.MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics and pharmacodynamics:principles of therapeutic drug monitoring. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 82–120.Google Scholar
- 24.Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation (CDER), Center for Biologics Evaluation and Research (CBER), May 2003.Google Scholar
- 29.Treatment Improvement Protocol (TIP) Series, No. 49. Chapter 4: oral naltrexone. Center for substance abuse treatment. Rockville: US Substance Abuse and Mental Health Services Administration; 2009.Google Scholar
- 33.Tompkins DA, Bigelow GE, Harrison JA, et al. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105:154–9.PubMedCentralPubMedCrossRefGoogle Scholar